Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06749106

Plaque Imaging in Routine Care to Detect Intraplaque Hemorrhage

The aim of this study is to investigate the association between intraplaque hemorrhage (IPH) detected by non-contrast magnetic resonance imaging (MRI) of the carotid artery in routine clinical practice and ipsilateral acute ischemic events. The investigators' overarching aim is to determine whether this sequence aids the diagnostic work-up of stroke patients.

For this purpose, the investigators set up a prospective single-center longitudinal observational study with one year follow-up. In addition, this study will analyze retrospectively obtained data collected through clinical routine.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institute for Stroke and Dementia Research

Munich, 81377, Germany

Location status: Recruiting

About this study

Stroke is one of the leading causes of death and the leading cause of permanent disability. Identifying the underlying etiology is crucial as secondary stroke prevention strategies vary depending on the cause of the stroke. However, in approximately 30% of patients, no clear etiology can be identified (cryptogenic stroke), preventing these patients from receiving targeted treatment.

Recent findings indicate that features of plaque vulnerability are associated with acute ischemic stroke which also applies to patients with cryptogenic stroke who have a carotid artery stenosis of less than 50%. Features of plaque vulnerability can be assessed by high-resolution carotid magnetic resonance imaging (MRI) which enables noninvasive detailed characterization of atherosclerotic carotid artery plaques. Hence, plaque imaging allows to detect vulnerable plaques and to further stratify stroke etiology. In addition, plaque imaging may identify patients with vulnerable plaques who are at risk for a recurrent ischemic stroke or TIA.

However, integrating multisequence high-resolution, contrast-enhanced MRI into the standard diagnostic workflow of acute stroke would prove difficult, thus calling for simpler imaging protocols. Unlike other features of plaque vulnerability, intraplaque hemorrhage (IPH) can be reliably detected by standard coils and conventional native black-blood fat-saturated T1-weighted sequences. Given the frequency of IPH, previous study results, and additional literature evidencing the importance of IPH as a marker for plaque vulnerability and risk of stroke recurrence, a single black-blood fat-saturated T1-weighted sequence was added to the MR imaging protocol for the diagnostic work-up of stroke patients at LMU hospital.

Patients with acute ischemic stroke, who received non-contrast carotid MRI for routine diagnostic work-up, will be asked whether they are willing to participate in a prospective, longitudinal study with telephone follow-up to assess recurrent ischemic stroke or TIA. In addition, this study will analyse retrospectively obtained data collected through clinical routine. These analyses will be done on all patients who received non-contrast carotid MRI for routine diagnostic work-up over the last years. This approach allows to estimate the prevalence of IPH in an unselected patient population.

In principle, the detection of IPH points towards the presence of an increased plaque vulnerability. However, it is unknown whether IPH can be reliably detected on routine clinical scans and whether information on the presence or absence of IPH should influence clinical decision making. Depending on the results, the outcome of this study might benefit future generations of patients by improving the diagnostic assignment to a specific stroke etiology and risk assessment with respect to recurrent vascular events.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with acute ischemic stroke
  • Availability of non-contrast carotid MRI scans obtained through routine diagnostic work-up

Exclusion criteria

  • Infarct in the posterior circulation or bilateral ischemic infarcts
  • Time between symptom onset and non-contrast carotid MRI > 10 days
  • Prior stenting of a carotid artery or carotid endarterectomy
  • Age < 18 years
  • Life expectancy < 1 year
  • Inability to provide written informed consent

This eligibility criteria apply for the prospective part of the PARADE study.

Treatment and study plan

Primary outcomes

  1. intraplaque hemorrhage (IPH)

    Time frame: baseline

    presence of IPH as detected on routine non-contrast MRI

Secondary outcomes

  1. recurrent ischemic stroke or TIA

    Time frame: 3 months, 12 months

    recurrent ischemic stroke or transient ischemic attack (TIA)

  2. Plaque-RADS

    Time frame: baseline

    scoring plaque vulnerability according to the Plaque-RADS (Reporting and Data System) classification (score [1-4] with higher scores meaning higher plaque vulnerability) with all data available from clinical routine

  3. Barthel Scale

    Time frame: baseline, 3 months, 12 months

    activities of daily living, assessed using the Barthel Scale (score [0-100] with lower scores meaning lower independence in activities of daily living)

  4. modified Rankin Scale (mRS)

    Time frame: baseline, 3 months, 12 months

    modified Rankin Scale (mRS) as a functional global outcome scale measuring the level of disability after stroke (score [0-6] with higher scores meaning a worse outcome)

  5. National Institutes of Health Stroke Scale (NIHSS)

    Time frame: baseline

    stroke severity, assessed using the National Institutes of Health Stroke Scale (NIHSS) (score [0-42] with higher scores meaning higher stroke severity)

Study contacts

Contact information is provided by the study sponsor or research team.

Anna Kopczak, MD

CONTACT

Martin Dichgans, Prof.

CONTACT

[email protected]

+49 89 4400 46019

Sponsors and collaborators

Lead sponsor

Ludwig-Maximilians - University of Munich

Other

Collaborators

  • LMU Klinikum

Registry information

Acronym: PARADE

Important dates

Study start
2025
Primary completion
2028
Study completion
2029
First posted
Dec 27, 2024
Registry last updated
Jan 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.